Extracellular HSP90: An emerging target for cancer therapy

Current Signal Transduction Therapy

Volumn 4, Issue 1, 2009, Pages 51-58

  Sidera, Katerina ^a   Patsavoudi, Evangelia ^a,b  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b UNIVERSITY OF WEST ATTICA   (Greece)

Author keywords

Cancer therapeutics; Cell invasion; Extracellular HSP90; Signal transduction

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 4 [4 (1,4 BENZODIOXAN 6 YL) 5 METHYL 1H PYRAZOL 3 YL] 6 ETHYLRESORCINOL; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NOVOBIOCIN; PROTEIN KINASE B; PROTEIN P53; PURINE DERIVATIVE; PYRAZOLE; RADAMYCIN; RADICICOL; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER INVASION; CARCINOGENESIS; CELL MOTILITY; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC STABILITY; GENETIC TRANSFORMATION; HUMAN; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 65449120730     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436209787048739     Document Type: Review

References (104)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-99.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
3. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-65.
4. Martin GS. Cell signaling and cancer. Cancer Cell 2003; 4: 167-74.
5. Downward J. The ins and outs of signalling. Nature 2001; 411: 759-62.
6. Hunter T. Signaling-2000 and beyond. Cell 2000; 100: 113-27.
7. Ritossa F. A new puffing pattern induced by temperature shock and DNP in Drosophila. Experientia 1962; 19: 571-573.
8. Ritossa F. Discovery of the heat shock response. Cell Stress Chaperones 1996; 1: 97-8.
9. Lindquist S. The heat-shock response. Annu Rev Biochem 1986; 55: 1151-91.
10. Morimoto RI. Cells in stress: transcriptional activation of heat shock genes. Science 1993; 259: 1409-10.
11. Parsell DA, Lindquist S. The function of heat-shock proteins in stress tolerance: degradation and reactivation of damaged proteins. Annu Rev Genet 1993; 27: 437-96.
12. Bukau B, Horwich AL. The Hsp70 and Hsp60 chaperone machines. Cell 1998; 92: 351-66.
13. Hartl FU. Molecular chaperones in cellular protein folding. Nature 1996; 381: 571-9.
14. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002; 295: 1852-8.
15. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006; 31: 164-72.
16. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003; 3: 213-7.
17. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002; 2: 3-24.
18. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-72.
19. Buchner J. Hsp90 & Co. - a holding for folding. Trends Biochem Sci 1999; 24: 136-41.
20. Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006; 75: 271-94.
21. Picard D. Heat-shock protein 90, a chaperone for folding and regulation. Cell Mol Life Sci 2002; 59: 1640-8.
22. Young JC, Moarefi I, Hartl FU. Hsp90: a specialized but essential protein-folding tool. J Cell Biol 2001; 154: 267-73.
23. Sreedhar AS, Kalmar E, Csermely P, Shen YF. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 2004; 562: 11-5.
24. Argon Y, Simen BB. GRP94, an ER chaperone with protein and peptide binding properties. Semin Cell Dev Biol 1999; 10: 495-505.
25. Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB, Toft DO. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem 2000; 275: 3305-12.
26. Versteeg S, Mogk A, Schumann W. The Bacillus subtilis htpG gene is not involved in thermal stress management. Mol Gen Genet 1999; 261: 582-8.
27. Borkovich KA, Farrelly FW, Finkelstein DB, Taulien J, Lindquist S. hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures. Mol Cell Biol 1989; 9: 3919-30.
28. Pratt WB. The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. Annu Rev Pharmacol Toxicol 1997; 37: 297-326.
29. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 1997; 18: 306-60.
30. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003; 228: 111-33.
31. Prodromou C, Panaretou B, Chohan S, Siligardi G, O'Brien R, Ladbury JE. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. EMBO J 2000; 19: 4383-92.
32. Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 2003; 3: 301-23.
33. Prodromou C, Roe SM, Piper PW, Pearl LH. A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone. Nat Struct Biol 1997; 4: 477-82.
34. Richter K, Muschler P, Hainzl O, Reinstein J, Buchner J. Sti1 is a non-competitive inhibitor of the Hsp90 ATPase. Binding prevents the N-terminal dimerization reaction during the atpase cycle. J Biol Chem 2003; 278: 10328-33.
35. Pearl LH, Prodromou C. Structure and in vivo function of Hsp90. Curr Opin Struct Biol 2000; 10: 46-51.
36. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004; 3: 1021-30.
37. Chaudhury S, Welch TR, Blagg BS. Hsp90 as a target for drug development. Chem Med Chem 2006; 1: 1331-40.
38. Neckers L, Mimnaugh E, Schulte TW. Hsp90 as an anti-cancer target. Drug Resist Updat 1999; 2: 165-172.
39. Scheibel T, Buchner J. The Hsp90 complex--a super-chaperone machine as a novel drug target. Biochem Pharmacol 1998; 56: 675-82.
40. Smith DF, Whitesell L, Katsanis E. Molecular chaperones: biology and prospects for pharmacological intervention. Pharmacol Rev 1998; 50: 493-514.
41. Workman P. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone. Cancer Detect Prev 2002; 26: 405-10.
42. Workman P. Overview: translating Hsp90 biology into Hsp90 drugs. Curr Cancer Drug Targets 2003; 3: 297-300.
43. Ferrarini M, Heltai S, Zocchi MR, Rugarli C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 1992; 51: 613-9.
44. McCarthy MM, Pick E, Kluger Y, Gould-Rothberg B, Lazova R, Camp RL. HSP90 as a marker of progression in melanoma. Ann Oncol 2008; 19: 590-4.
45. Yufu Y, Nishimura J, Nawata H. High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. Leuk Res 1992; 16: 597-605.
46. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002; 8: S55-61.
47. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003; 15: 419-24.
48. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003; 100: 13791-6.
49. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000; 97: 10832-7.
50. Schulte TW, Blagosklonny MV, Ingui C, Neckers L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 1995; 270: 24585-8.
51. Pandey P, Saleh A, Nakazawa A, Kumar S, Srinivasula SM, Kumar V. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. Embo J 2000; 19: 4310-22.
52. Takayama S, Reed JC, Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 2003; 22: 9041-7.
53. Whitesell L, Bagatell R, Falsey R. The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 2003; 3: 349-58.
54. Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature 1998; 396: 336-42.
55. Chiosis G, Vilenchik M, Kim J, Solit D. Hsp90: the vulnerable chaperone. Drug Discov Today 2004; 9: 881-8.
56. Sharma SV, Agatsuma T, Nakano H. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 1998; 16: 2639-45.
57. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994; 91: 8324-8.
58. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997; 90: 65-75.
59. Schulte TW, An WG, Neckers LM. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun 1997; 239: 655-9.
60. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997; 89: 239-50.
61. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995; 36: 305-15.
62. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005; 23: 4152-61.
63. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999; 91: 1940-9.
64. Pacey S, Banerji U, Judson I, Workman P. Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 2006; 172: 331-58.
65. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998; 42: 273-9.
66. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 2007; 32: 517-30.
67. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007; 1113: 202-16.
68. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 407-10.
69. Neckers L, Lee YS. Cancer: the rules of attraction. Nature 2003; 425: 357-9.
70. Ullrich SJ, Robinson EA, Law LW, Willingham M, Appella E. A mouse tumor-specific transplantation antigen is a heat shock-related protein. Proc Natl Acad Sci USA 1986; 83: 3121-5.
71. Basu S, Srivastava PK. Heat shock proteins: the fountainhead of innate and adaptive immune responses. Cell Stress Chaperones 2000; 5: 443-51.
72. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 2007; 81: 15-27.
73. Binder RJ, Vatner R, Srivastava P. The heat-shock protein receptors: some answers and more questions. Tissue Antigens 2004; 64: 442-51.
74. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001; 14: 303-13.
75. Binder RJ, Srivastava PK. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Natl Acad Sci USA 2004; 101: 6128-33.
76. Triantafilou M, Triantafilou K. Heat-shock protein 70 and heat-shock protein 90 associate with Toll-like receptor 4 in response to bacterial lipopolysaccharide. Biochem Soc Trans 2004; 32: 636-9.
77. Sapozhnikov AM, Ponomarev ED, Tarasenko TN, Telford WG. Spontaneous apoptosis and expression of cell surface heat-shock proteins in cultured EL-4 lymphoma cells. Cell Prolif 1999; 32: 363-78.
78. Liao DF, Jin ZG, Baas AS, Daum G, Gygi SP, Aebersold R. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem 2000; 275: 189-96.
79. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004; 6: 507-14.
80. Sidera K, Samiotaki M, Yfanti E, Panayotou G, Patsavoudi E. Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system. J Biol Chem 2004; 279: 45379-88.
81. Sidera K, Gaitanou M, Stellas D, Matsas R, Patsavoudi E. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J Biol Chem 2008; 283: 2031-41.
82. Becker B, Multhoff G, Farkas B, Wild PJ, Landthaler M, Stolz W. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol 2004; 13: 27-32.
83. Stellas D, Karameris A, Patsavoudi E. Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. Clin Cancer Res 2007; 13: 1831-8.
84. Li W, Li Y, Guan S, Fan J, Cheng CF, Bright AM. Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. Embo J 2007; 26: 1221-33.
85. Tsutsumi S, Scroggins B, Koga F, Lee MJ, Trepel J, Felts S. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 2008; 27: 2478-87.
86. Cheng CF, Guan S, Fedesco M, Fan J, Li Y, Bandyopadhyay B. TGF {alpha}-Stimulated Secretion of HSP90{alpha}: Using LRP-1/CD91 Receptor To Promote Human Skin Cell Migration Against TGF {beta}-Rich Environment In Wound Healing. Mol Cell Biol 2008; 28: 3344-58.
87. Yang Y, Rao R, Shen J, Tang Y, Fiskus W, Nechtman J. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res 2008; 68: 4833-42.
88. Tsutsumi S, Neckers L. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci 2007; 98: 1536-9.
89. Bausero MA, Page DT, Osinaga E, Asea A. Surface expression of Hsp25 and Hsp72 differentially regulates tumor growth and metastasis. Tumour Biol 2004; 25: 243-51.
90. El Hamidieh A, Siganou A, Grammatikakis N, Patsavoudi E. Cdc37 is localized at the cell surface and is possibly involved in cancer cell invasion. FEBS J 2008; 275: 201.
91. Eustace BK, Jay DG. Extracellular roles for the molecular chaperone, hsp90. Cell Cycle 2004; 3: 1098-100.
92. Farkas B, Hantschel M, Magyarlaki M, Becker B, Scherer K, Landthaler M. Heat shock protein 70 membrane expression and melanoma-associated marker phenotype in primary and metastatic melanoma. Melanoma Res 2003; 13: 147-52.
93. Lee KJ, Kim YM, Kim DY, Jeoung D, Han K, Lee ST. Release of heat shock protein 70 (Hsp70) and the effects of extracellular Hsp70 on matric metalloproteinase-9 expression in human monocytic U937 cells. Exp Mol Med 2006; 38: 364-74.
94. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell 1996; 84: 359-69.
95. Webb DJ, Parsons JT, Horwitz AF. Adhesion assembly, disassembly and turnover in migrating cells -- over and over and over again. Nat Cell Biol 2002; 4: E97-100.
96. Feldner JC, Brandt BH. Cancer cell motility--on the road from c-erbB-2 receptor steered signaling to actin reorganization. Exp Cell Res 2002; 272: 93-108.
97. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362-74.
98. Miranti CK, Brugge JS. Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol 2002; 4: E83-90.
99. Murphy G, Gavrilovic J. Proteolysis and cell migration: creating a path? Curr Opin Cell Biol 1999; 11: 614-21.
100. Seiki M. The cell surface: the stage for matrix metalloproteinase regulation of migration. Curr Opin Cell Biol 2002; 14: 624-32.
101. Wozniak MA, Modzelewska K, Kwong L, Keely PJ. Focal adhesion regulation of cell behavior. Biochim Biophys Acta 2004; 1692: 103-19.
102. Citri A, Kochupurakkal BS, Yarden Y. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004; 3: 51-60.
103. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996; 271: 22796-801.
104. Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 2001; 276: 3702-8.